secwatch.observer — SEC 8-K summary
======================================

Issuer:     COGNITION THERAPEUTICS INC (CGTX)
CIK:        0001455365
Form:       8-K
Filed at:   2023-03-28T23:59:59+00:00
Accession:  0001104659-23-037397
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cognition Therapeutics reports CT1812 alters Alzheimer's disease biomarkers in meta-analysis of 24 patients
--------------------------------------------------------------------------------

- Meta-analysis of 24 participants (SHINE-A) and full SPARC dataset showed CT1812 significantly alters 28 biomarkers.
- 11 of 28 biomarkers are priority Alzheimer's targets; effects seen on clusterin (CLU) and prion protein (PRPN).
- Pathways affected include synapse health, neuroinflammation, and amyloid-β biology, consistent with mechanism.
- Data presented at AD/PD 2023 conference; management says findings strengthen understanding of CT1812's effect on Aβ oligomer-driven neurotoxicity.
- Ongoing trials expected to read out in coming months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1455365/000110465923037397/0001104659-23-037397-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1455365/000110465923037397/tm2310682d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-037397

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer